PTJ
NMRA icon

Paul Tudor Jones’s Neumora Therapeutics NMRA Stock Holding History

Paul Tudor Jones’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.52M Buy
3,835,200
+3,280,000
+591% +$6.24M 0.01% 1095
2026
Q1 		$1.08M Buy
+555,200
New +$1.44M ﹤0.01% 2316

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's NMRA Position: Q2 2026 in Review

Paul Tudor Jones increased its Neumora Therapeutics (NMRA) stake by 76% in Q2 2026, buying an estimated $1.11M and bringing the position to 1,356,147 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

Paul Tudor Jones first reported a position in NMRA in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Paul Tudor Jones held 1,356,147 shares of Neumora Therapeutics worth $2.31M as of Q2 2026.
  • Paul Tudor Jones bought 584,729 Neumora Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Neumora Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1851 holding.
  • Paul Tudor Jones first reported a position in Neumora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.